Nov 12 (Reuters) - Promis Neurosciences Inc PMN.TO :
* Announces acquisition of exclusive worldwide license to novel therapeutic
target for alzheimer's disease
* Says acquired an exclusive, worldwide license to a novel alzheimer's disease
target
* Says the amino acid sequence of this novel target has not been disclosed
* Says novel target is on misfolded beta amyloid, implicated in the development
and progression of alzheimer's
* Acquired the exclusive, worldwide license pursuant to expanded license agreement with university of British Columbia
* Source text for Eikon ID:nCNW3CsSJa
* Further company coverage PMN.TO